Athira Pharma IncChange company Symbol lookupSelect an option...ATHA Athira Pharma IncAGIL AgileThought IncDNA Ginkgo Bioworks Holdings IncFCF First Commonwealth Financial CorpARMN Aris Mining CorpIBM International Business Machines CorpJPM JPMorgan Chase & CoGEHC GE Healthcare Technologies IncGE General Electric CoPFE Pfizer IncGo
Athira Pharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing small molecules to restore neuronal health and stop neurodegeneration. Its pipeline consists of both blood brain barrier (BBB) permeable and peripherally restricted drug candidates for the central nervous system (CNS), peripheral nervous system (PNS), and other indications. Its lead candidate, fosgonimeton (ATH-1017), is a subcutaneously administered, small molecule positive modulator of the hepatocyte growth factor/mesenchymal-epithelial transition factor (HGF/MET) system for CNS disorders. It is also advancing potential drug candidates for neuropathic pain, amyotrophic lateral sclerosis (ALS), and other neurodegenerative diseases. Its neuropathic pain drug candidate, ATH-1020, completed a Phase I single ascending dose evaluation in healthy volunteers. Its ATH-1105 is a small molecule compound designed to be an orally available, once-daily treatment to enhance the HGF/MET system.
|
|
|
|
| |
Upcoming Events
Past Earnings
GAAP vs. Non-GAAP Earnings
TD Ameritrade displays two types of stock earnings numbers, which are calculated differently and may report different values for the same period. GAAP earnings are the official numbers reported by a company, and non-GAAP earnings are adjusted to be more readable in earnings history and forecasts.
| Date | Event description | Earnings per share actual | Earnings estimate range | Previous year's actual |
|---|---|---|---|---|
| August 10, 2023 | Q2 2023 Earnings Release | -$0.78 | -$0.84 to -$0.679 | -$0.65 |
| May 11, 2023 | Q1 2023 Earnings Release | -$0.73 | -$0.66 to -$0.58 | -$0.56 |
| March 23, 2023 | Q4 2022 Earnings Release | -$0.53 | -$0.71 to -$0.62 | -$0.45 |
| November 10, 2022 | Q3 2022 Earnings Release | -$0.53 | -$0.69 to -$0.57 | -$0.42 |
Earnings Calendar and Events Data provided by |Terms of Use| © 2023 Wall Street Horizon, Inc.
, , , Copyright © 2023. All rights reserved.
Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.
Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.